JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target

JMP Securities analyst Jason Butler reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Market Outperform and maintains $9 price target.

BenzingaJun 27 00:03

JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9

JMP Securities analyst Jason Butler maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 38

Futu NewsJun 26 04:32 · Ratings

Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows

On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film.Anaphylm

BenzingaJun 26 01:00

Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $7

Lake Street analyst Thomas Flaten maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and adjusts the target price from $8 to $7.According to TipRanks data, the analyst has a success rate o

Futu NewsJun 25 21:33 · Ratings

Aquestive Gains After Initial Data for Allergy Candidate

Seeking AlphaJun 25 21:29

Express News | Aquestive Therapeutics: Sees Filing Nda Shortly After Completion of Pediatric Study of Anaphylm

BreakingsJun 25 20:04